ストックスクリーナーアプリを入手
4.06
0.49%
-0.02
アフターアワーズ：
4.06
Astria Therapeutics Inc (ATXS) 最新ニュース
Raymond James Financial Inc. Takes $707,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Long Term Trading Analysis for (ATXS) - news.stocktradersdaily.com
Teacher Retirement System of Texas Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
Astria Therapeutics Grants $235K Worth of Stock Options to Strategic New Hires - Stock Titan
Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $26.60 - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Increases Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Investment Report - news.stocktradersdaily.com
What is Lifesci Capital’s Forecast for ATXS FY2025 Earnings? - The AM Reporter
Q1 EPS Forecast for Astria Therapeutics Decreased by Analyst - Defense World
Lifesci Capital Has Pessimistic View of ATXS FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for ATXS Q1 Earnings? - Defense World
Astria Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
(ATXS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Astria Therapeutics price target raised to $28 from $27 at Wedbush - TipRanks
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating - Marketscreener.com
Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright - Defense World
Astria Therapeutics Advances Clinical Trials and Financials - TipRanks
Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating - TipRanks
Astria Therapeutics, Inc. SEC 10-K Report - TradingView
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - BioSpace
Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating - TipRanks
Preclinical data reported for Astria’s anti-OX40 monoclonal antibody - BioWorld Online
Astria Therapeutics posts marginally smaller-than-expected quarterly net loss per share - Marketscreener.com
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by New York State Common Retirement Fund - Defense World
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.67 - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Astria Therapeutics Issues 87,450 Stock Options: What This Means for Shareholder Dilution - Stock Titan
Learn to Evaluate (ATXS) using the Charts - news.stocktradersdaily.com
Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics (ATXS) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Press Release From Business Wire: Astria Therapeutics, Inc. - UrduPoint News
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema - Business Wire
Can Astria's Navenibart Change the Game for HAE Patients? Phase 3 Trial Begins After 95% Attack Reduction - Stock Titan
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference - Business Wire
Can Astria Therapeutics' Conference Appearance Signal New Developments in Allergic Disease Treatments? - Stock Titan
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance
When the Price of (ATXS) Talks, People Listen - Stock Traders Daily
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business Wire
Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average – What’s Next? - Defense World
Astria Therapeutics: A High-Conviction Bet On HAE - Seeking Alpha
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Price Target from Analysts - Defense World
How to Take Advantage of moves in (ATXS) - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Target Price from Brokerages - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Now Covered by Analysts at JMP Securities - MarketBeat
Angioedema Pipeline 2024: Therapies Under Investigation, - openPR
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference - sharewise
4.35%
10.53%
大文字化:
|
ボリューム (24 時間):